CMVLF (Cellectis) EPS without NRI: $-0.48 (TTM As of Mar. 2026)


CMVLF Cellectis SA CMVLF
60 GF Score
Price $3.47
GF Value $3.71
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Cellectis EPS without NRI?

Cellectis CMVLF 60 EPS without NRI is $-0.48 as of Mar. 2026. GuruFocus rates CMVLF with a GF Score™ of 60/100 and a GF Value™ of $3.71 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,170 Biotechnology companies, Cellectis ranks better than 74.02% on this metric.

Cellectis's earnings per share without non-recurring items for the three months ended in Mar. 2026 was $-0.23. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.48.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 36.50% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 21.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Cellectis's EPS without NRI or its related term are showing as below:

CMVLF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -132.4   Med: 3.15   Max: 54.6
Current: 36.5

During the past 13 years, Cellectis's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 54.60% per year. The lowest was -132.40% per year. And the median was 3.15% per year.

CMVLF's 3-Year EPS without NRI Growth Rate is ranked better than
74.02% of 1170 companies
in the Biotechnology industry
Industry Median: 16.75 vs CMVLF: 36.50

Cellectis's EPS (Diluted) for the three months ended in Mar. 2026 was $-0.18. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.67.

Cellectis's EPS (Basic) for the three months ended in Mar. 2026 was $-0.18. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.67.


Cellectis  (OTCPK:CMVLF) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Cellectis EPS without NRI Related Terms


Cellectis EPS without NRI Historical Data

* Premium members only.

The historical data trend for Cellectis's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cellectis EPS without NRI Chart

Cellectis Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.27 -2.15 -1.71 -0.62 -0.61

Cellectis Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.13 -0.10 0.09 -0.24 -0.23

CMVLF vs VRTX, REGN, ALNY: EPS without NRI Comparison

For the Biotechnology subindustry, Cellectis's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cellectis PE Ratio without NRI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellectis's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Cellectis's PE Ratio without NRI falls into.


CMVLF
60GF Score
Cellectis SA CMVLF
EPS without NRI is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cellectis EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of $-0.48 mean?
Cellectis (CMVLF) has a EPS without NRI of $-0.48 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Cellectis and its competitors. According to the industry distribution chart, Cellectis ranks #304 out of 1170 companies in the Biotechnology industry, placing it in the top 26%.
Is Cellectis' EPS without NRI too high?
Cellectis' current EPS without NRI is $-0.48. Based on the distribution chart, Cellectis ranks #304 out of 1170 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Cellectis has a GF Score™ of 60/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cellectis' EPS without NRI compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cellectis ranks #304 out of 1170 companies for EPS without NRI. This puts Cellectis in the upper half of its industry. The industry median EPS without NRI is 16.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Biotechnology company?
The median EPS without NRI among Biotechnology companies is 16.75, based on 1,170 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Cellectis and its competitors. For the Biotechnology industry, the median EPS without NRI is 16.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cellectis's current EPS without NRI is $-0.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellectis stock overvalued right now?
Based on GuruFocus' analysis, Cellectis (CMVLF) is currently considered Fairly Valued. The stock's GF Value™ is $3.71, compared to a current price of $3.47 — trading 6.5% below its estimated fair value. The current EPS without NRI is $-0.48. Cellectis' overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Cellectis (CMVLF), the current EPS without NRI is $-0.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cellectis (CMVLF) Overvalued in 2026?

Based on GuruFocus' analysis, Cellectis stock appears to be undervalued. The current stock price of $3.47 is trading 6.5% below its estimated GF Value™ of $3.71. GuruFocus considers Cellectis to be Fairly Valued.

Key valuation signals for CMVLF:

  • EPS without NRI: $-0.48
  • GF Value™: $3.71 vs. price of $3.47 (6.5% below fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the CMVLF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cellectis Business Description

Address 8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
60GF Score

Get the complete analysis for CMVLF

EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.47
Price
$3.71
GF Value